

# **Middle East Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Biologics) By Synthesis (Synthetic, Biotech), By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2025 - 2033**

<https://marketpublishers.com/r/MF176AC60429EN.html>

Date: September 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: MF176AC60429EN

## **Abstracts**

### Market Size & Trends

The Middle East active pharmaceutical ingredient CDMO market size was estimated at USD 7.23 billion in 2024 and is projected to reach USD 11.64 billion by 2033, growing at a CAGR of 5.58% from 2025 to 2033. The market is driven by the growing prevalence of chronic diseases, a focus on generic and biosimilar drugs, and significant technological advancements. Supportive government policies, investment in pharmaceutical infrastructure, and streamlined regulatory processes further stimulate domestic and international players to expand operations in the region.

In addition, the shifting preference of pharmaceutical companies toward outsourcing complex manufacturing processes rather than investing heavily in in-house capabilities is also one of the factors contributing to the market growth. Outsourcing these activities helps pharmaceutical companies to focus more resources on innovation, clinical research, and market expansion. These factors reduce financial risks, shorten development timelines, and allow for faster scalability, which is particularly valuable in a region where healthcare demand is rising rapidly. Furthermore, global players are showing increasing interest in entering the Middle Eastern market due to its strategic geographic location, which offers access to both developed and emerging economies, making it an attractive hub for pharmaceutical trade and distribution.

Furthermore, increasing government initiatives aimed at strengthening local drug manufacturing to ensure regional supply security are also one of the factors fueling the market growth. Several countries in the region are prioritizing domestic production capabilities to reduce dependence on imports and improve access to essential medicines. This has opened opportunities for CDMOs that can provide advanced technologies and regulatory expertise to support local firms. In parallel, a growing number of collaborations and joint ventures between multinational pharmaceutical companies and regional players are accelerating knowledge transfer and boosting overall manufacturing capacity.

### Middle East Active Pharmaceutical Ingredient CDMO Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, workflow, and country:

Product Outlook (Revenue, USD Million, 2021 - 2033)

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Biologics

Synthesis Outlook (Revenue, USD Million, 2021 - 2033)

Synthetic

Biotech

Drug Outlook (Revenue, USD Million, 2021 - 2033)

Innovative

Generics

Workflow Outlook (Revenue, USD Million, 2021 - 2033)

Clinical

Commercial

Application Outlook (Revenue, USD Million, 2021 - 2033)

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

Country Outlook (Revenue, USD Million, 2021 - 2033)

Saudi Arabia

UAE

Kuwait

Oman

Qatar

**This report can be delivered to the clients within 2 Business Days**

## Contents

### **CHAPTER 1. METHODOLOGY AND SCOPE**

- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
  - 1.4.1. Purchased database
  - 1.4.2. GVR's internal database
  - 1.4.3. Secondary sources
  - 1.4.4. Primary research
- 1.5. Information or Data Analysis
  - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
  - 1.7.1. Commodity flow analysis (Model 1)
  - 1.7.2. Value chain based analysis (Model 2)
  - 1.7.3. Multivariate Analysis (Model 3)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

### **CHAPTER 2. EXECUTIVE SUMMARY**

- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

### **CHAPTER 3. MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: VARIABLES, TRENDS, & SCOPE**

- 3.1. Market Lineage Outlook
  - 3.1.1. Parent Market Outlook
  - 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
  - 3.2.1. Market Driver Analysis
  - 3.2.2. Market Restraint Analysis
  - 3.2.3. Market Opportunities

- 3.3. Technological Landscape
- 3.4. Pricing Model Analysis
- 3.5. Supply Chain Analysis
- 3.6. Market Analysis Tools
  - 3.6.1. Porter's Five Forces Analysis
  - 3.6.2. PESTEL by SWOT Analysis

## **CHAPTER 4. MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: PRODUCT ESTIMATES & TREND ANALYSIS**

- 4.1. Segment Dashboard
- 4.2. Middle East Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
- 4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
  - 4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
- 4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
  - 4.5.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Biologics
  - 4.6.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 5. MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: SYNTHESIS ESTIMATES & TREND ANALYSIS**

- 5.1. Segment Dashboard
- 5.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Synthesis Movement Analysis
- 5.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033 (USD Million)
- 5.4. Synthetic
  - 5.4.1. Synthetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Biotech
  - 5.5.1. Biotech Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 6. MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: DRUG ESTIMATES & TREND ANALYSIS**

- 6.1. Segment Dashboard

6.2. Middle East Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis

6.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)

6.4. Innovative

6.4.1. Innovative Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.5. Generics

6.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 7. MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: APPLICATION ESTIMATES & TREND ANALYSIS**

7.1. Segment Dashboard

7.2. Middle East Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis

7.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)

7.4. Oncology

7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.5. Hormonal

7.5.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.6. Glaucoma

7.6.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.7. Cardiovascular disease

7.7.1. Cardiovascular disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.8. Diabetes

7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.9. Others

7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 8. MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS**

8.1. Segment Dashboard

8.2. Middle East Active Pharmaceutical Ingredient CDMO Market: Workflow Movement Analysis

8.3. Middle East Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)

#### 8.4. Clinical

8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

#### 8.5. Commercial

8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

### **CHAPTER 9. MIDDLE EAST ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: COUNTRY ESTIMATES & TREND ANALYSIS**

#### 9.1. Regional Market Dashboard

#### 9.2. Regional Market Snapshot

#### 9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:

#### 9.4. Saudi Arabia

9.4.1. Key Country Dynamics

9.4.2. Competitive Scenario

9.4.3. Regulatory Framework

9.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)

#### 9.5. UAE

9.5.1. Key Country Dynamics

9.5.2. Competitive Scenario

9.5.3. Regulatory Framework

9.5.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)

#### 9.6. Kuwait

9.6.1. Key Country Dynamics

9.6.2. Competitive Scenario

9.6.3. Regulatory Framework

9.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

#### 9.7. Oman

9.7.1. Key Country Dynamics

9.7.2. Competitive Scenario

9.7.3. Regulatory Framework

9.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

#### 9.8. Qatar

9.8.1. Key Country Dynamics

9.8.2. Competitive Scenario

9.8.3. Regulatory Framework

9.8.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

### **CHAPTER 10. COMPETITIVE LANDSCAPE**

- 10.1. Company Categorization
  - 10.1.1. Market Leaders
  - 10.1.2. Emerging Players
- 10.2. Company Market Share Analysis, 2024
- 10.3. Company Profiles
  - 10.3.1. Cambrex Corporation
    - 10.3.1.1. Company Overview
    - 10.3.1.2. Financial Performance
    - 10.3.1.3. Product/Service Benchmarking
    - 10.3.1.4. Strategic Initiatives
  - 10.3.2. Recipharm AB
    - 10.3.2.1. Company Overview
    - 10.3.2.2. Financial Performance
    - 10.3.2.3. Product/Service Benchmarking
    - 10.3.2.4. Strategic Initiatives
  - 10.3.3. Thermo Fisher Scientific Inc.
    - 10.3.3.1. Company Overview
    - 10.3.3.2. Financial Performance
    - 10.3.3.3. Product/Service Benchmarking
    - 10.3.3.4. Strategic Initiatives
  - 10.3.4. CordenPharma International
    - 10.3.4.1. Company Overview
    - 10.3.4.2. Financial Performance
    - 10.3.4.3. Product/Service Benchmarking
    - 10.3.4.4. Strategic Initiatives
  - 10.3.5. Samsung Biologics
    - 10.3.5.1. Company Overview
    - 10.3.5.2. Financial Performance
    - 10.3.5.3. Product/Service Benchmarking
    - 10.3.5.4. Strategic Initiatives
  - 10.3.6. Lonza
    - 10.3.6.1. Company Overview
    - 10.3.6.2. Financial Performance
    - 10.3.6.3. Product/Service Benchmarking
    - 10.3.6.4. Strategic Initiatives
  - 10.3.7. Catalent, Inc.
    - 10.3.7.1. Company Overview
    - 10.3.7.2. Financial Performance
    - 10.3.7.3. Product/Service Benchmarking

- 10.3.7.4. Strategic Initiatives
- 10.3.8. Siegfried Holding AG
  - 10.3.8.1. Company Overview
  - 10.3.8.2. Financial Performance
  - 10.3.8.3. Product/Service Benchmarking
  - 10.3.8.4. Strategic Initiatives
- 10.3.9. Piramal Pharma Solutions
  - 10.3.9.1. Company Overview
  - 10.3.9.2. Financial Performance
  - 10.3.9.3. Product/Service Benchmarking
  - 10.3.9.4. Strategic Initiatives
- 10.3.10. Boehringer Ingelheim International GmbH
  - 10.3.10.1. Company Overview
  - 10.3.10.2. Financial Performance
  - 10.3.10.3. Product/Service Benchmarking
  - 10.3.10.4. Strategic Initiatives

## List Of Tables

### LIST OF TABLES

Table 1 List of abbreviation

Table 2 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)

Table 3 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)

Table 4 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)

Table 5 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

Table 6 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

Table 7 Middle East Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)

Table 8 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)

Table 9 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)

Table 10 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)

Table 11 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

Table 12 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

Table 13 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)

Table 14 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)

Table 15 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)

Table 16 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

Table 17 UAE Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

Table 18 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)

Table 19 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)

Table 20 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)

Table 21 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

Table 22 Kuwait Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

Table 23 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)

Table 24 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)

Table 25 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)

Table 26 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

Table 27 Oman Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

Table 28 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by product, 2021 - 2033 (USD Million)

Table 29 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)

Table 30 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)

Table 31 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

Table 32 Qatar Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

## List Of Figures

### LIST OF FIGURES

- Fig. 1 Middle East Active Pharmaceutical Ingredient CDMO Market Segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Market formulation & validation
- Fig. 7 Commodity flow analysis
- Fig. 8 Value-Chain-Based Sizing & Forecasting
- Fig. 9 QFD model sizing & forecasting
- Fig. 10 Bottom-up approach
- Fig. 11 Market snapshot
- Fig. 12 Segment snapshot 1
- Fig. 13 Segment snapshot 2
- Fig. 14 Segment snapshot 3
- Fig. 15 Competitive landscape snapshot
- Fig. 16 Parent market outlook, 2024 (USD Million)
- Fig. 17 Ancillary market outlook, 2024 (USD Million)
- Fig. 18 Middle East Active Pharmaceutical Ingredient CDMO Market dynamics
- Fig. 19 Total R&D drug pipeline size, 2021 - 2024
- Fig. 20 Total drug pipeline by development phase, 2024
- Fig. 21 Porter's five forces analysis
- Fig. 22 PESTEL analysis
- Fig. 23 Middle East Active Pharmaceutical Ingredient CDMO Market Product outlook: Segment dashboard
- Fig. 24 Middle East Active Pharmaceutical Ingredient CDMO Market, by Product segment: Market share, 2025 & 2033
- Fig. 25 Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 26 Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 27 Biologics market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 28 Middle East Active Pharmaceutical Ingredient CDMO Market Synthesis outlook: Segment dashboard
- Fig. 29 Middle East Active Pharmaceutical Ingredient CDMO Market, by Synthesis segment: Market share, 2025 & 2033

- Fig. 30 Synthetic market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 31 Biotech market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 32 Middle East Active Pharmaceutical Ingredient CDMO Market Drug outlook: Segment dashboard
- Fig. 33 Middle East Active Pharmaceutical Ingredient CDMO Market, by Drug segment: Market share, 2025 & 2033
- Fig. 34 Innovative market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 35 Generics market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 36 Middle East Active Pharmaceutical Ingredient CDMO Market Application outlook: Segment dashboard
- Fig. 37 Middle East Active Pharmaceutical Ingredient CDMO Market, by Application segment: Market share, 2025 & 2033
- Fig. 38 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 39 Hormonal market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 40 Glaucoma market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 41 Cardiovascular disease market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 42 Diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 43 Others market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 44 Middle East Active Pharmaceutical Ingredient CDMO Market Workflow outlook: Segment dashboard
- Fig. 45 Middle East Active Pharmaceutical Ingredient CDMO Market, by Workflow segment: Market share, 2025 & 2033
- Fig. 46 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 47 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 48 Regional market: Key takeaways
- Fig. 49 Regional marketplace: Key takeaways
- Fig. 50 Middle East Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 51 Key country dynamics
- Fig. 52 Saudi Arabia Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 53 Key country dynamics
- Fig. 54 Kuwait Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 55 Key country dynamics
- Fig. 56 UAE Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 57 Key country dynamics

Fig. 58 Oman Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 59 Key country dynamics

Fig. 60 Qatar Active Pharmaceutical Ingredient CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 61 Market participant categorization

Fig. 62 Heat map analysis

## I would like to order

Product name: Middle East Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Biologics) By Synthesis (Synthetic, Biotech), By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/MF176AC60429EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF176AC60429EN.html>